DETAILS, FICTION AND GENETIC METHYLATION TEST

underneath equally Drake’s and Lynch’s versions, the cost of deleterious mutations is what drives mutation premiums down (Drake 1991; Lynch 2010; Sung et al. 2012). consequently, under each products, a rise in the normal cost of mutations would lead to a reduce in mutation costs. to look at this, Drake examined mutation fees of thermophiles and